🇺🇸 ABBV — AbbVie Inc.

Salud Compra
← Volver

Precio actual

288,84 USD

Máx. histórico

294,89

3 días

Caída desde máximo

-2,05%

Rango 52 semanas

190,75 – 298,74

Variación hoy

-2,05%

Cierre anterior

294,89

Rango de hoy

286,14 – 294,86

Volumen hoy

8.835.948

Peor caída histórica

-45,09%

26/01/2018 → 15/08/2019

Recuperado en 477 días

Volatilidad anualizada ⓘ

26,29%

Información
Nombre completo
AbbVie Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Drug Manufacturers - General
Empleados
57.000
PER ⓘ
49,63 (puede no estar actualizado)
Dividend yield
2,35% (puede no estar actualizado)
Precio objetivo analistas
298,50 USD (puede no estar actualizado)
Primera cotización
02/01/2013
Precio actualizado
hace 20 horas
Sobre la empresa

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Dividendos repartidos Total últimos 12 meses: 6,9200 USD · Yield: 2,40%
Fecha de pago Importe por participación
15/10/2026 1,7300 USD
15/07/2026 1,7300 USD
15/04/2026 1,7300 USD
16/01/2026 1,7300 USD
15/10/2025 1,6400 USD
15/07/2025 1,6400 USD
15/04/2025 1,6400 USD
15/01/2025 1,6400 USD
15/10/2024 1,5500 USD
15/07/2024 1,5500 USD
12/04/2024 1,5500 USD
12/01/2024 1,5500 USD
12/10/2023 1,4800 USD
13/07/2023 1,4800 USD
13/04/2023 1,4800 USD
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
13/02/2013 35,42 35,57 35,15 35,27 -0,42% 1,19% 4.859.800
12/02/2013 35,77 35,90 35,20 35,42 -1,20% 1,96% 7.473.800
11/02/2013 36,13 36,18 35,75 35,85 -1,10% 1,19% 6.032.100
08/02/2013 36,37 36,42 35,83 36,25 -0,47% 1,62% 13.858.700
07/02/2013 37,57 37,57 35,80 36,42 -1,94% 4,71% 9.872.500
06/02/2013 36,96 37,28 36,86 37,14 -0,16% 1,14% 5.738.900
05/02/2013 37,42 37,73 37,18 37,20 -0,21% 1,47% 7.284.400
04/02/2013 36,64 37,30 36,55 37,28 +0,27% 2,05% 6.348.000
01/02/2013 36,84 37,20 36,52 37,18 +1,34% 1,85% 9.527.500
31/01/2013 36,84 36,93 36,27 36,69 -0,65% 1,79% 10.720.700
30/01/2013 36,81 37,53 36,81 36,93 -1,02% 1,96% 10.841.800
29/01/2013 36,71 37,46 36,25 37,31 +1,14% 3,30% 8.838.500
28/01/2013 37,65 37,87 36,71 36,89 -1,89% 3,08% 7.140.100
25/01/2013 37,52 37,84 36,64 37,60 +0,37% 3,20% 8.934.600
24/01/2013 37,79 38,52 37,23 37,46 -0,90% 3,41% 11.327.100
23/01/2013 36,91 37,84 36,50 37,80 +3,79% 3,63% 10.981.600
22/01/2013 36,98 37,25 35,93 36,42 -2,41% 3,57% 15.809.700
18/01/2013 36,43 37,32 36,04 37,32 +2,47% 3,51% 17.842.200
17/01/2013 35,75 36,70 35,75 36,42 +2,48% 2,66% 14.424.800
16/01/2013 34,47 35,54 34,45 35,54 +2,72% 3,16% 16.512.700
15/01/2013 33,71 34,72 33,71 34,60 +1,50% 3,00% 13.040.200
14/01/2013 34,01 34,25 33,80 34,09 +0,71% 1,32% 11.584.900
11/01/2013 33,59 33,90 33,35 33,85 -0,44% 1,64% 11.191.500
10/01/2013 33,66 34,00 33,33 34,00 +0,29% 1,99% 15.658.100
09/01/2013 33,61 33,95 33,61 33,90 +0,56% 1,01% 18.800.400
08/01/2013 34,29 34,64 33,36 33,71 -2,18% 3,73% 17.863.300
07/01/2013 34,15 35,45 34,15 34,46 +0,20% 3,81% 17.897.100
04/01/2013 34,62 34,89 34,25 34,39 -1,26% 1,85% 21.372.100
03/01/2013 35,00 35,00 34,16 34,83 -0,83% 2,40% 16.739.300
02/01/2013 34,92 35,40 34,10 35,12 — 3,72% 13.767.900